Cover Image

Prevalence of Late-Onset Multiple Sclerosis in Fars Province, Southern Iran

Sadegh Izadi, Maryam Sharifian, Alireza Nikseresht, Shima Rafiee

Background: Multiple Sclerosis (MS) is the most common demyelinating and inflammatory disease of the central nevus system especially in young adults, but in a subgroup of patients the first clinical symptoms present after the age of 50. This clinical presentation is defined as Late-Onset Multiple Sclerosis (LOMS). The incidence and prevalence of MS including LOMS vary geographically. The aim of this study is to determine epidemiological characteristics of LOMS in Fars province, South of Iran.Materials and  Methods: All patients aged over 50, known to have had definite MS according to MC Donald’s criteria, being members of Shiraz University Multiple Sclerosis Database (SUMSD), were evaluated in this study. The following data were recorded via a questionnaire indicating gender, age at the time of diagnosis, clinical course and details of disease- modifying therapies (Beta-Interferon).Results: Among a total of 1705 patients, 7.2% were identified as having LOMS and 3.1% identified as having very late-onset MS (VLOMS). Mean age of the patients with LOMS at the time of diagnosis was 58.81 ± 2.6 years  (20.8% were male and 107 (79.2%) were female). 8.9 % had EDSS 6 and more. 89.1% of patients received Beta-Interferon as a disease-modifying treatment including Avonex (16.3 %), Cinovex (32.6%), Rebif (14.1%) and Betaferon (26.1 %). Conclusion: In our study, 7.2% of all MS patients were identified as LOMS. In LOMS subgroup, clinical history and para-clinical data should be thoroughly evaluated to exclude more common conditions like cerebrovascular disease. [GMJ. 2014;3(4):228-31]

PrLate-Onset Multiple Sclerosis; Pevalence; Epidemiological Characteristic; Fars; Southern Iran

Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25; 372(9648):1502-17.

Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004 Oct; 61(10):1613-5

Noseworthy J, Paty D, Wonnacott T, et al. Multiple sclerosis after age 50.Neurology 1983; 33:1537–44.

Kis B, Rumberg B, Berlit P. Clinical characteristics of patients with late-onsetmultiple sclerosis. J Neurol 2008;255:697–702.

Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008 Mar;7(3):268-77.

Hader WJ, Elliot M, Ebers GC. Epidemiology of multiple sclerosis in London and Middleast Country, Ontario, Canada. Neurology 1988;38:617–21.

Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain2003;126:770–82.

McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121-127.

Saadatnia M, Etemadifar M, Maghzi AH. Multiple sclerosis in Isfahan Iran. Int Rev Neurobiol. 2007; 79:357-75.

Azzimondi G, Stracciari A, Rinaldi R, et al. Multiple sclerosis with very lateonset: report of six cases and review of the literature. Eur Neurol1994; 34:332–6.

Martinelli V, Rodegher M, Moiola L, Comi G. Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci. 2004 Nov;25 Suppl 4:S350-5.

Polliack ML, Barak Y, Achiron A. Late-onset multiple sclerosis. J Am GeriatrSoc2001;49:168–171

Tremlett H, Devonshire V. Is late-onset multiple sclerosis associated with a worse outcome? Neurology. 2006 Sep 26;67(6):954-9.

Leary SM; Miller DH; Stevenson VL; Brex PA; Chard DT; Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.Neurology 2003 Jan 14; 60(1):44-51.

Qiu W, Wu JS, Castley A, James I, Joseph J, Christiansen FT, et al. Clinical profile and HLA-DRB1 genotype of late onset multiple sclerosis in Western Australia. J Clin Neurosci. 2010 Aug;17(8):1009-13. Epub 2010 May 23.


  • There are currently no refbacks.